Safety and efficacy of hydroxyurea and eflornithine against most blood parasites Babesia and Theileria.

Abstract

BACKGROUND:

The plenteous resistance to and undesirable consequences of the existing antipiroplasmic therapies have emphasized the urgent need for new chemotherapeutics and drug targets for both prophylaxis and chemotherapy. Hydroxyurea (HYD) is an antineoplastic agent with antitrypanosomal activity. Eflornithine (α-difluoro-methyl ornithine, DFMO) is the best choice therapy for the treatment of late-stage Gambian human African trypanosomiasis.

METHODS:

In this study, the inhibitory and combination efficacy of HYD and DFMO with existing babesicidal drugs (diminazene aceturate (DA), atovaquone (ATV), and clofazimine (CLF)) deoxyribonucleotide in vitro against the multiplication of Babesia and Theileria. As well as, their chemotherapeutic effects were assessed on B. microti strain that infects rodents. The Cell Counting Kits-8 (CCK-8) test was used to examine their cytotoxicity on human foreskin fibroblast (HFF), mouse embryonic fibroblast (NIH/3T3), and Madin-Darby bovine kidney (MDBK) cells.

FINDINGS:

HYD and DFMO suppressed the multiplication of all tested species (B. bigemina, B. bovis, B. caballi, B. divergens, and T. equi) in a dose-related manner. HFF, NIH/3T3, or MDBK cell viability was not influenced by DFMO at 1000 μM, while HYD affected the MDBK cell viability at EC50 value of 887.5±14.4 μM. The in vitro combination treatments of DFMO and HYD with CLF, DA, and ATV exhibited synergistic and additive efficacy toward all tested species. The in vivo experiment revealed that HYD and DFMO oral administration at 100 and 50 mg/kg inhibited B. microti multiplication in mice by 60.1% and 78.2%, respectively. HYD-DA and DFMO-DA combined treatments showed higher chemotherapeutic efficacy than their monotherapies.

CONCLUSION:

These results indicate the prospects of HYD and DFMO as drug candidates for piroplasmosis treatment, when combined mainly with DA, ATV, and CLF. Therefore, further studies are needed to combine HYD or DFMO with either ATV or CLF and examine their impact on B. microti infection in mice.

• Authors: Gaber El-Saber Batiha, Amany Magdy Beshbishy, Oluyomi Stephen Adeyemi, Eman Nadwa, Eman Rashwan, Naoaki Yokoyama, Ikuo Igarashi
• Journal: PloS one (PLoS One) Vol. 15 Issue 2 Pg. e0228996 ( 2020) ISSN: 1932-6203 [Electronic] United States
• PMID: 32053698 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Antiprotozoal Agents
• Clofazimine
• diminazene aceturate
• Hydroxyurea
• Diminazene
• Atovaquone
• Eflornithine

Topics

• Animals
• Antineoplastic Agents
• Antiprotozoal Agents (administration & dosage, pharmacology)
• Atovaquone (adverse effects, pharmacology)
• Babesia (drug effects)
• Cell Survival (drug effects)
• Clofazimine (adverse effects, pharmacology)
• Diminazene (adverse effects, analogs & derivatives, pharmacology)
• Dogs
• Eflornithine (adverse effects, pharmacology)
• Foreskin (cytology)
• Humans
• Hydroxyurea (adverse effects, pharmacology)
• Male
• Mice
• NIH 3T3 Cells
• Theileria (drug effects)